bupropion and Pregnancy studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.

Research Excerpts

Excerpt	Relevance	Reference
"There were no significant differences in the safety measures across the treatment arms and bupropion was not efficacious in promoting smoking cessation at the end of treatment (7-day point prevalence quit rates: bupropion, 11."	9.41	Placebo-controlled trial of bupropion for smoking cessation in pregnant women. ( Hand, DJ; Hoffman, M; Kranzler, HR; Oncken, C; Schnoll, RA; Srinivas, S; Washio, Y; Wileyto, EP; Zindel, LR, 2021)
"We searched MEDLINE, EMBASE, CINAHL, and PsychINFO databases for studies of any design reporting pregnancy outcomes after bupropion or varenicline exposure."	9.01	Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. ( Coleman, T; Jones, M; Turner, E; Vaz, LR, 2019)
"While more studies are needed, research to date suggests that bupropion may be a reasonable treatment option for depressed pregnant women who require pharmacotherapy, particularly when they also are attempting to reduce nicotine use during pregnancy."	8.95	Bupropion Use During Pregnancy: A Systematic Review. ( Gitlin, MJ; Hendrick, V; Ortiz-Portillo, E; Suri, R, 2017)
"Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide."	8.81	Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002)
"Bupropion is used for treatment of depression during pregnancy."	7.83	Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016)
"Fetal and neonatal exposure to the smoking cessation drug bupropion, unlike NRT, does not appear to adversely affect metabolic outcomes or the fertility of the female offspring."	7.79	Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. ( De Long, N; Gerstein, HC; Holloway, AC; Hyslop, JR; Morrison, KM; Nicholson, CJ, 2013)
" The mother had received bupropion, an antidepressant and aid to smoking cessation, throughout pregnancy."	7.77	Hyperinsulinism associated with gestational exposure to bupropion in a newborn infant. ( Gisslen, T; Nathan, B; Rao, R; Thompson, T, 2011)
"Reports from the GlaxoSmithKline Bupropion Pregnancy Registry suggested an increase in cardiovascular defects following exposure to bupropion during pregnancy."	7.74	Bupropion in pregnancy and the prevalence of congenital malformations. ( Cole, JA; Cosmatos, IS; Haight, BR; Modell, JG; Stoler, JM; Walker, AM, 2007)
"Bupropion was developed for the treatment of depression, but subsequently was found to be effective for smoking cessation."	7.73	Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. ( Boshier, A; Chun-Fai-Chan, B; Einarson, A; Fayez, I; Kalra, S; Koren, G; Shakir, S; Voyer-Lavigne, S, 2005)
"Bupropion (Zyban) is the first new pharmacological treatment for smoking cessation to be introduced since nicotine replacement therapy."	7.72	Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. ( Boshier, A; Shakir, SA; Wilton, LV, 2003)
"Treatment with nicotine replacement therapy or bupropion doubles the one-year success rate after cessation of smoking."	6.41	[Treatment of nicotine addiction. Drug therapy for smoking cessation]. ( Christensen, HR; Døssing, M; Pedersen, ST, 2002)
" Paired t tests were used to compare pharmacokinetic parameters during pregnancy and postpartum."	5.62	Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. ( Czuba, LC; Fay, EE; Isoherranen, N; Sager, JE; Shum, S; Stephenson-Famy, A, 2021)
"There were no significant differences in the safety measures across the treatment arms and bupropion was not efficacious in promoting smoking cessation at the end of treatment (7-day point prevalence quit rates: bupropion, 11."	5.41	Placebo-controlled trial of bupropion for smoking cessation in pregnant women. ( Hand, DJ; Hoffman, M; Kranzler, HR; Oncken, C; Schnoll, RA; Srinivas, S; Washio, Y; Wileyto, EP; Zindel, LR, 2021)
"We included randomised controlled trials (RCTs), cluster-RCTs and factorial RCTs, which measured smoking cessation at six months or longer, recruited adults who smoked combustible cigarettes at enrolment (excluding pregnant people) and randomised them to approved pharmacotherapies and technologies used for smoking cessation worldwide (varenicline, cytisine, nortriptyline, bupropion, nicotine replacement therapy (NRT) and e-cigarettes) versus no pharmacological intervention, placebo (control) or another approved pharmacotherapy."	5.41	Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. ( Agrawal, S; Aveyard, P; Fanshawe, TR; Freeman, SC; Hajizadeh, A; Hartmann-Boyce, J; Lindson, N; Livingstone-Banks, J; Ordóñez-Mena, JM; Sutton, AJ; Theodoulou, A; Zhu, S, 2023)
"(3) An increased risk of birth defects, particularly cardiac malformations, is also suspected after exposure to amphetamine derivatives during pregnancy."	5.33	Bupropion (amfebutamone): caution during pregnancy. ( , 2005)
"Individual smoking cessation counseling along with the twice-daily use of 150 mg bupropion sustained release increased smoking cessation rates and reduced cravings and total nicotine withdrawal symptoms during the treatment period."	5.24	Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. ( Ahmed, MS; Clark, SM; Feinn, RS; Fokina, VM; Hankins, GDV; Jain, SK; Nanovskaya, TN; Oncken, C; West, H, 2017)
"This initial attempt to evaluate bupropion for smoking cessation during pregnancy will inform future trial methodology."	5.20	Randomized, controlled pilot trial of bupropion for pregnant smokers: challenges and future directions. ( Blackwell, S; Blalock, JA; Cinciripini, PM; Minnix, JA; Mullen, PD; Northrup, TF; Pedroza, C; Stotts, AL, 2015)
"Bupropion's efficacy for smoking cessation in pregnant women is unknown."	5.14	The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. ( Brigham, EP; Chisolm, MS; Jones, HE; Strain, EC; Tuten, M, 2010)
" When used by non-pregnant smokers, pharmacotherapies (nicotine replacement therapy (NRT), bupropion, and varenicline) are effective for increasing smoking cessation, however their efficacy and safety in pregnancy remains unknown."	5.05	Pharmacological interventions for promoting smoking cessation during pregnancy. ( Berlin, I; Chamberlain, C; Claire, R; Coleman, T; Cooper, SE; Davey, MA; Leonardi-Bee, J, 2020)
"We searched MEDLINE, EMBASE, CINAHL, and PsychINFO databases for studies of any design reporting pregnancy outcomes after bupropion or varenicline exposure."	5.01	Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. ( Coleman, T; Jones, M; Turner, E; Vaz, LR, 2019)
"While more studies are needed, research to date suggests that bupropion may be a reasonable treatment option for depressed pregnant women who require pharmacotherapy, particularly when they also are attempting to reduce nicotine use during pregnancy."	4.95	Bupropion Use During Pregnancy: A Systematic Review. ( Gitlin, MJ; Hendrick, V; Ortiz-Portillo, E; Suri, R, 2017)
" Nous avons mené des recherches dans les bases de données PubMed, Medline, EMBASE et Cochrane en vue d’en tirer les études pertinentes (1990-2014) au moyen des termes de recherche suivants : smoking cessation, pregnancy, medicine, behavioural, nicotine replacement products, bupropion et varenicline."	4.91	Smoking Cessation Strategies in Pregnancy. ( Davies, GA; Leung, LW, 2015)
"To determine the efficacy and safety of smoking cessation pharmacotherapies (including NRT, varenicline and bupropion), other medications, or ENDS when used for smoking cessation in pregnancy."	4.91	Pharmacological interventions for promoting smoking cessation during pregnancy. ( Chamberlain, C; Coleman, T; Cooper, SE; Davey, MA; Leonardi-Bee, J, 2015)
"Cochrane systematic review evidence from 2013 suggests that adding mood management to behavioural support may improve cessation outcomes in smokers with current or past depression and strengthens evidence for previous conclusions, including the safety of varenicline and bupropion and the benefits of behavioural support for smoking cessation in pregnancy."	4.90	Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. ( Cahill, K; Hartmann-Boyce, J; Lancaster, T; Stead, LF, 2014)
"There are insufficient data at this time to recommend the use of varenicline and/or bupropion for smoking cessation during pregnancy."	4.90	Is it safe to use smoking cessation therapeutics during pregnancy? ( Barra, NG; De Long, NE; Hardy, DB; Holloway, AC, 2014)
" To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline."	4.87	Pharmacotherapy for smoking cessation: present and future. ( Aubin, HJ; Karila, L; Reynaud, M, 2011)
" This review article provides an overview of comprehensive (the 5 A's framework: Ask, Advise, Assess, Assist, Arrange) and brief (Ask, Advise, Refer) interventions for assisting patients with quitting, and a more detailed review of the seven first-line pharmacological agents for smoking cessation (nicotine replacement therapy formulations, bupropion SR and varenicline) and combination therapy regimens."	4.86	Current approaches to pharmacotherapy for smoking cessation. ( Corelli, RL; Hudmon, KS; Prokhorov, AV, 2010)
" There are now eight effective pharmacotherapies (nicotine gum, patch, nasal spray, inhaler, lozenge/tablet, bupropion, nortriptyline and clonidine) available to aid smoking cessation."	4.83	Developments in pharmacotherapy for tobacco dependence: past, present and future. ( Foulds, J; Steinberg, MB; Williams, JM; Ziedonis, DM, 2006)
"Nicotine addiction has been identified as the primary contributor to continued widespread tobacco use worldwide."	4.81	Managing nicotine addiction. ( Hatsukami, DK; Kotlyar, M, 2002)
" All forms of nicotine replacement therapy (NRT) -- gum, patches and inhaler -- and bupropion are safe and effective for increasing smoking cessation rates in the short and long terms."	4.81	The pharmacotherapy of smoking cessation. ( Morgan, LC; Peters, MJ, 2002)
" The general population model included age, hepatitis C virus infection, days of opioid used by type, number of cigarettes used daily, and the following medications used in the last 30 day of pregnancy: bupropion, antinausea medicines, benzodiazepines, antipsychotics, and gabapentin."	4.02	Development and Validation of a Model to Predict Neonatal Abstinence Syndrome. ( Cooper, WO; Dudley, J; Harrell, FE; Hartmann, K; Martin, PR; Patrick, SW; Slaughter, JC; Stratton, S, 2021)
"Providers were more concerned about bupropion and varenicline than other medications within the same pregnancy risk categories."	3.96	Health-care providers' concern regarding smoking cessation pharmacotherapies during pregnancy: Calls to a teratology information service. ( Havard, A; Kennedy, D; Lee, ML; Tran, DT; Welsh, A, 2020)
"Pregnant smokers recruited to participate in a placebo-controlled trial of bupropion for smoking cessation provided a blood sample for measurement of NMR."	3.96	Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. ( Hand, D; Kranzler, HR; Lynch, KG; Oncken, C; Schnoll, R; Tyndale, RF; Washio, Y; Zindel, LR, 2020)
"Bupropion (BUP) has a potential to be an effective pharmacotherapy for smoking cessation during pregnancy."	3.85	The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone. ( Ahmed, MS; Fokina, VM; Hankins, GDV; Nanovskaya, T; Oncken, C; Patrikeeva, SL, 2017)
"Bupropion is used for treatment of depression during pregnancy."	3.83	Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. ( Ahmed, MS; Clark, SM; Fokina, VM; Hankins, GD; Nanovskaya, TN; Oncken, C; West, H, 2016)
"Bupropion and nicotine patch replacement therapy have an impact on smoking cessation during and after pregnancy."	3.83	Success of smoking cessation interventions during pregnancy. ( Bérard, A; Sheehy, O; Zhao, JP, 2016)
"The use of antidepressant drug bupropion hydrochloride (BPN) during pregnancy results in increased cardiovascular anomalies."	3.80	Evaluation of bupropion hydrochloride developmental cardiotoxic effects in chick cardiomyocyte micromass culture and stem cell derived cardiomyocyte systems. ( Latif, ML; Parker, TL; Pratten, MK; Shaikh Qureshi, WM, 2014)
" Exposure categories included first-trimester bupropion alone or in combination with other antidepressants, first-trimester antidepressants other than bupropion, and no exposure to any antidepressant at any time from 2 months prior to pregnancy through delivery."	3.80	First-trimester exposure to bupropion and risk of cardiac malformations. ( Kerr, S; Louik, C; Mitchell, AA, 2014)
" This infant was reported to be free from typical perinatal risk factors of hyperinsulinism except for the fact that the mother of the baby was receiving the antidepressant bupropion during her pregnancy."	3.79	Bupropion can close KATP channel and induce insulin secretion. ( Dezaki, K; Galvanovskis, J; Iwasaki, Y; Maejima, Y; Nakata, M; Sakuma, K; Shimomura, K; Yada, T; Yang, Y, 2013)
"Fetal and neonatal exposure to the smoking cessation drug bupropion, unlike NRT, does not appear to adversely affect metabolic outcomes or the fertility of the female offspring."	3.79	Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. ( De Long, N; Gerstein, HC; Holloway, AC; Hyslop, JR; Morrison, KM; Nicholson, CJ, 2013)
"Bupropion, an amphetamine, is authorised as an aid to smoking cessation, despite its negative harm-benefit balance."	3.78	Bupropion: congenital heart defects (continued). ( , 2012)
" The mother had received bupropion, an antidepressant and aid to smoking cessation, throughout pregnancy."	3.77	Hyperinsulinism associated with gestational exposure to bupropion in a newborn infant. ( Gisslen, T; Nathan, B; Rao, R; Thompson, T, 2011)
"In order to evaluate the potential use of bupropion as smoking cessation therapy during pregnancy, the aim of this investigation was to determine transplacental transfer and metabolism of bupropion and its distribution among placental tissue and maternal and fetal circuits of the dually perfused placental lobule."	3.76	Transplacental transfer and metabolism of bupropion. ( Abdelrahman, DR; Ahmed, MS; Earhart, AD; Hankins, GD; Nanovskaya, T; Patrikeeva, S; Wang, X, 2010)
"We identified a positive association between early pregnancy bupropion use and left outflow tract heart defects; however, the magnitude of the observed increased risk was small."	3.76	Maternal use of bupropion and risk for congenital heart defects. ( Alwan, S; Botto, LD; Correa, A; Friedman, JM; Rasmussen, SA; Reefhuis, J, 2010)
"Children of mothers treated with bupropion during pregnancy have an increased risk of being diagnosed with ADHD; a possible causal effect needs to be further studied."	3.76	Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. ( Figueroa, R, 2010)
"Reports from the GlaxoSmithKline Bupropion Pregnancy Registry suggested an increase in cardiovascular defects following exposure to bupropion during pregnancy."	3.74	Bupropion in pregnancy and the prevalence of congenital malformations. ( Cole, JA; Cosmatos, IS; Haight, BR; Modell, JG; Stoler, JM; Walker, AM, 2007)
"Bupropion was developed for the treatment of depression, but subsequently was found to be effective for smoking cessation."	3.73	Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. ( Boshier, A; Chun-Fai-Chan, B; Einarson, A; Fayez, I; Kalra, S; Koren, G; Shakir, S; Voyer-Lavigne, S, 2005)
"Bupropion (Zyban) is the first new pharmacological treatment for smoking cessation to be introduced since nicotine replacement therapy."	3.72	Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. ( Boshier, A; Shakir, SA; Wilton, LV, 2003)
"Smoking during pregnancy has detrimental effects on mother and fetus."	2.87	Smoking Cessation Following Text Message Intervention in Pregnant Women. ( Chamness, D; Forinash, AB; Gross, G; Inteso, C; Koerner, J; Mathews, K; Miller, C; Yancey, A, 2018)
"Bupropion SR was well tolerated, and no subjects discontinued treatment as a result of medication side-effects."	2.71	Bupropion SR for the treatment of postpartum depression: a pilot study. ( Cohen, LS; Nonacs, RM; Pearson, K; Poitras, JR; Soares, CN; Viguera, AC, 2005)
"Perinatal depression is associated with serious risks for the mother, baby, and family."	2.58	Pharmacotherapy for Perinatal Depression. ( Albertini, ES; Ernst, C; Fersh, ME; Habib, S; Khan, SJ; Lusskin, SI, 2018)
" A few minor adverse effects and serious adverse effects were reported in several studies."	2.48	Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta-analysis. ( Ju, W; Jung, HS; Kim, H; Myung, SK; Oh, SW; Park, CH; Seo, H, 2012)
"Bupropion was effective at long-term follow-up (pooled OR 1."	2.46	A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. ( Agboola, S; Coleman, T; Leonardi Bee, J; McNeill, A, 2010)
"Smoking during pregnancy is a significant public health concern."	2.42	Pharmacotherapies to enhance smoking cessation during pregnancy. ( Kranzler, HR; Oncken, CA, 2003)
"Treatment with nicotine replacement therapy or bupropion doubles the one-year success rate after cessation of smoking."	2.41	[Treatment of nicotine addiction. Drug therapy for smoking cessation]. ( Christensen, HR; Døssing, M; Pedersen, ST, 2002)
" Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures."	1.62	Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. ( Brajcich, MR; Marks, J; Messer, RD; Murphy, ME; Palau, MA, 2021)
"Varenicline may increase the risk of coronary events."	1.38	Promoting smoking cessation. ( Larzelere, MM; Williams, DE, 2012)
"Bupropion was metabolized by baboon hepatic and placental microsomes to hydroxybupropion (OH-BUP), threo- (TB) and erythrohydrobupropion (EB)."	1.37	Metabolism of bupropion by baboon hepatic and placental microsomes. ( Abdelrahman, DR; Ahmed, MS; Fokina, VM; Hankins, GD; Nanovskaya, TN; Wang, X, 2011)
"Bupropion was transported by BCRP (K(t) 3 microM, V(max) 30 pmol/mg protein/min) and P-gp (K(t) 0."	1.36	Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. ( Abdelrahman, DR; Ahmed, MS; Hankins, GD; Hemauer, SJ; Nanovskaya, TN; Patrikeeva, SL; Wang, X, 2010)
"Smoking during pregnancy is the largest modifiable risk factor for pregnancy-related morbidity and mortality."	1.36	Bupropion metabolism by human placenta. ( Abdelrahman, DR; Ahmed, MS; Hankins, GD; Nanovskaya, TN; Patrikeeva, SL; Wang, X; Zharikova, OL, 2010)
"(3) An increased risk of birth defects, particularly cardiac malformations, is also suspected after exposure to amphetamine derivatives during pregnancy."	1.33	Bupropion (amfebutamone): caution during pregnancy. ( , 2005)

Research

Studies (107)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Birth Outcomes 5-minute Appearance, Pulse, Grimace, Activity, and Respiration Score

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (1.87)	18.7374
1990's	1 (0.93)	18.2507
2000's	32 (29.91)	29.6817
2010's	58 (54.21)	24.3611
2020's	14 (13.08)	2.80

Authors	Studies
Marks, C	1
Silvola, R	1
Teal, E	1
Quinney, SK	1
Haas, DM	1
Levander, XA	1
Carmody, T	1
Cook, RR	1
Potter, JS	1
Trivedi, MH	1
Korthuis, PT	1
Shoptaw, S	1
Speck, ML	1
Gomes, ALA	1
Rojas, CS	1
Willig, JB	1
Herrmann, AP	1
Pilger, DA	1
Rates, SMK	1
Rábade-Castedo, C	1
de Granda-Orive, JI	1
Riesco-Miranda, JA	1
De Higes-Martínez, E	1
Ramos-Pinedo, Á	1
Cabrera-César, E	1
Signes-Costa Miñana, J	1
García Rueda, M	1
Pastor-Esplá, E	1
Jiménez-Ruiz, CA	1
Lindson, N	1
Theodoulou, A	1
Ordóñez-Mena, JM	1
Fanshawe, TR	2
Sutton, AJ	1
Livingstone-Banks, J	3
Hajizadeh, A	1
Zhu, S	1
Aveyard, P	2
Freeman, SC	1
Agrawal, S	1
Hartmann-Boyce, J	5
Lee, ML	1
Tran, DT	1
Welsh, A	1
Kennedy, D	1
Havard, A	1
Claire, R	1
Chamberlain, C	2
Davey, MA	2
Cooper, SE	2
Berlin, I	2
Leonardi-Bee, J	2
Coleman, T	4
Kranzler, HR	4
Washio, Y	2
Zindel, LR	2
Lynch, KG	1
Hand, D	1
Tyndale, RF	1
Oncken, C	7
Schnoll, R	1
Anderson, KN	1
Lind, JN	1
Simeone, RM	1
Bobo, WV	1
Mitchell, AA	2
Riehle-Colarusso, T	1
Polen, KN	1
Reefhuis, J	3
Patrick, SW	1
Slaughter, JC	1
Harrell, FE	1
Martin, PR	1
Hartmann, K	1
Dudley, J	1
Stratton, S	1
Cooper, WO	1
Wileyto, EP	1
Srinivas, S	1
Hand, DJ	1
Hoffman, M	1
Schnoll, RA	1
Brajcich, MR	1
Palau, MA	1
Messer, RD	1
Murphy, ME	1
Marks, J	1
Fay, EE	1
Czuba, LC	1
Sager, JE	1
Shum, S	1
Stephenson-Famy, A	1
Isoherranen, N	2
Fan, T	2
Lee, G	1
Scheuermann, TS	1
Richter, KP	1
Jacobson, LT	1
Shireman, TI	1
Baraona, LK	1
Lovelace, D	1
Daniels, JL	1
McDaniel, L	1
Fokina, VM	5
Patrikeeva, SL	3
Hankins, GDV	2
Ahmed, MS	10
Nanovskaya, T	2
Hendrick, V	1
Suri, R	1
Gitlin, MJ	1
Ortiz-Portillo, E	1
Lusskin, SI	1
Khan, SJ	1
Ernst, C	1
Habib, S	1
Fersh, ME	1
Albertini, ES	1
Turner, E	1
Jones, M	1
Vaz, LR	1
Forinash, AB	1
Yancey, A	1
Chamness, D	1
Koerner, J	1
Inteso, C	1
Miller, C	1
Gross, G	1
Mathews, K	1
Barboza, J	1
Norris, E	1
West, R	2
Jarvis, M	1
Hajek, P	1
Hong, B	1
Wheat, H	1
Sanches, ESAM	1
Tsuzuki, F	1
Joinhas, F	1
Figueiras, GB	1
Moreira, EG	1
Salles, MJS	1
De Long, N	1
Hyslop, JR	1
Nicholson, CJ	1
Morrison, KM	1
Gerstein, HC	1
Holloway, AC	2
Aubin, HJ	2
Luquiens, A	1
Trivedi, D	1
Louik, C	1
Kerr, S	1
Freeman, MP	1
Stead, LF	1
Cahill, K	1
Lancaster, T	1
Rytting, E	2
Wang, X	6
Vernikovskaya, DI	2
Zhan, Y	1
Bauer, C	1
Abdel-Rahman, SM	1
Nanovskaya, TN	9
Stotts, AL	1
Northrup, TF	1
Cinciripini, PM	1
Minnix, JA	1
Blalock, JA	1
Mullen, PD	1
Pedroza, C	1
Blackwell, S	1
Shaikh Qureshi, WM	1
Latif, ML	1
Parker, TL	1
Pratten, MK	1
De Long, NE	1
Barra, NG	1
Hardy, DB	1
Patnode, CD	1
Henderson, JT	1
Thompson, JH	1
Senger, CA	1
Fortmann, SP	1
Whitlock, EP	1
Siu, AL	1
Leung, LW	1
Davies, GA	1
Blitz, J	1
West, H	3
Clark, SM	3
Hankins, GD	8
Bérard, A	1
Zhao, JP	1
Sheehy, O	1
Xu, M	1
Abdel-Rahman, SZ	1
Gopalakrishnan, K	1
More, AS	1
Kumar, S	1
Feinn, RS	1
Jain, SK	1
Hebert, R	1
Oztuna, F	1
Rore, C	1
Brace, V	1
Danielian, P	1
Williams, D	1
Tschabitscher, P	1
Homaier, I	1
Lichtenschopf, A	1
Groman, E	1
Earhart, AD	1
Patrikeeva, S	1
Abdelrahman, DR	5
Maritz, GS	1
Oncken, CA	2
Hudmon, KS	1
Corelli, RL	1
Prokhorov, AV	1
Zharikova, OL	1
Chisolm, MS	1
Brigham, EP	1
Tuten, M	1
Strain, EC	1
Jones, HE	1
Anderka, M	1
Romitti, PA	1
Sun, L	1
Druschel, C	1
Carmichael, S	1
Shaw, G	1
Alwan, S	2
Botto, LD	1
Rasmussen, SA	2
Correa, A	1
Friedman, JM	2
Leventhal, K	1
Byatt, N	1
Lundquist, R	1
Hemauer, SJ	1
Figueroa, R	1
Agboola, S	1
McNeill, A	2
Leonardi Bee, J	1
Karila, L	1
Reynaud, M	1
Gisslen, T	1
Nathan, B	1
Thompson, T	1
Rao, R	1
Mardle, T	1
Merrett, S	1
Wright, J	1
Percival, F	1
Lockhart, I	1
Schroeder, JW	1
Smith, AK	1
Brennan, PA	1
Conneely, KN	1
Kilaru, V	1
Knight, BT	1
Newport, DJ	1
Cubells, JF	1
Stowe, ZN	1
Larzelere, MM	1
Williams, DE	1
Myung, SK	1
Ju, W	1
Jung, HS	1
Park, CH	1
Oh, SW	1
Seo, H	1
Kim, H	1
Dickmann, LJ	1
Thyagarajan, V	1
Robin Clifford, C	1
Wurst, KE	1
Ephross, SA	1
Seeger, JD	1
Yang, Y	1
Shimomura, K	1
Sakuma, K	1
Maejima, Y	1
Iwasaki, Y	1
Galvanovskis, J	1
Dezaki, K	1
Nakata, M	1
Yada, T	1
Kotlyar, M	1
Hatsukami, DK	1
Baab, SW	1
Peindl, KS	1
Piontek, CM	1
Wisner, KL	1
Boshier, A	2
Wilton, LV	1
Shakir, SA	1
Dell, DL	1
O'Brien, BW	1
Benowitz, N	1
Dempsey, D	1
Chun-Fai-Chan, B	1
Koren, G	2
Fayez, I	1
Kalra, S	1
Voyer-Lavigne, S	1
Shakir, S	1
Einarson, A	2
Chan, B	1
Nonacs, RM	1
Soares, CN	1
Viguera, AC	1
Pearson, K	1
Poitras, JR	1
Cohen, LS	1
Foulds, J	1
Steinberg, MB	1
Williams, JM	1
Ziedonis, DM	1
Hsiao, SY	1
Cherng, CF	2
Yang, YK	1
Yeh, TL	1
Yu, L	2
Cole, JA	1
Modell, JG	1
Haight, BR	1
Cosmatos, IS	1
Stoler, JM	1
Walker, AM	1
Su, SW	1
Lin, YC	1
Rigotti, NA	1
Park, ER	1
Chang, Y	1
Regan, S	1
Crawford, JT	1
Tolosa, JE	1
Goldenberg, RL	2
Tucker, WE	1
Leibenluft, E	1
Okuyemi, KS	1
Ahluwalia, JS	1
Harris, KJ	1
Benowitz, NL	1
Dempsey, DA	1
Hughes, JR	1
Dolan-Mullen, P	1
Ogburn, PL	1
Orleans, CT	1
Slotkin, TA	1
Whiteside, HP	1
Yaffe, S	1
Raw, M	1
Pedersen, ST	1
Christensen, HR	1
Døssing, M	1
Peters, MJ	1
Morgan, LC	1
de Greef, WJ	1
Voogt, JL	1
Visser, TJ	1
Lamberts, SW	1
van der Schoot, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women[NCT02188459]	Phase 2	129 participants (Actual)	Interventional	2014-10-30	Completed
Smoking Cessation Following Text Message Intervention in Pregnant Women[NCT03024606]		49 participants (Actual)	Interventional	2014-03-31	Completed
"A Randomized Open-label, Superiority, Multicenter, Two-arm Intervention Study of the Effect of High-intensity vs. 'Low-intensity' Smoking Cessation Intervention in Active Smokers With COPD"[NCT04088942]	Phase 4	0 participants (Actual)	Interventional	2023-07-01	Withdrawn (stopped due to No funding)
The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study[NCT02788851]		70 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
Bupropion for Smoking Cessation During Pregnancy[NCT01390246]	Phase 4	65 participants (Actual)	Interventional	2011-07-31	Completed
Effectiveness of WhatsApp Online Group Discussion for Smoking Relapse Prevention: a Pragmatic Randomized Controlled Trial[NCT03760224]		928 participants (Actual)	Interventional	2018-10-04	Completed
Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226]		1,431 participants (Actual)	Observational	2007-09-30	Completed
Assessment of the Effectiveness of Nicotine Replacement Therapies (Nicotine Patches Delivering Nicotine 16 h/24 h) in 400 Pregnant Smokers. Randomized, Placebo-controlled, Multicenter, National Study. The SNIPP.[NCT00507975]	Phase 3	404 participants (Actual)	Interventional	2007-11-30	Completed
A Retrospective, Real-life Evaluation of the Cardiovascular Disease Risk Associated With Exposure to Pharmacological Smoking Cessation Interventions in a Representative UK Primary Care Patient Population.[NCT02195739]		61,050 participants (Actual)	Observational	2013-09-30	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Birth outcomes obtained from labor and delivery records 5-minute Appearance, Pulse, Grimace, Activity, and Respiration score (APGAR). The Apgar score has a range from 0 to 10. A 5-minute Apgar score of 7-10 as reassuring, a score of 4-6 as moderately abnormal, and a score of 0-3 as low in the term infant and late-preterm infant 6. (NCT02188459)
Timeframe: postpartum

Birth Outcomes for Gestational Age

Intervention	score on a scale (Mean)
Bupropion	8.9
Placebo	8.6

Birth outcomes obtained from labor and delivery records gestational age, measured in weeks. (NCT02188459)
Timeframe: Postpartum

Birth Outcomes Head Circumference.

Intervention	weeks (Mean)
Bupropion	37.1
Placebo	38.1

Birth outcomes obtained from labor and delivery records head circumference measured in centimeters. (NCT02188459)
Timeframe: Postpartum

Birth Outcomes, Size (Percentile) for Gestational Age.

Intervention	cm (Mean)
Bupropion	33.3
Placebo	33.0

Birth outcomes obtained from labor and delivery records infant size for gestational age, whether small for gestational age (i.e., <10th percentile birth weight for gestational age as determined by the Alexander curve). (NCT02188459)
Timeframe: Postpartum

Birth Weight Outcomes

Intervention	percentile (Mean)
Bupropion	32.0
Placebo	32.5

Birth weight outcomes were obtained from labor and delivery clinical records. Birth weight is measure in grams. (NCT02188459)
Timeframe: Postpartum

Number Moderate or Severe Side Effects

Intervention	grams (Mean)
Bupropion	2925.9
Placebo	2996.5

For adverse effects, our primary outcome will be the frequency of moderate or severe side effects from a checklist of bupropion-related side effects (derived from completed bupropion studies), as well as those elicited with open-ended questions, through regular obstetrics visits, and assessments triggered by any pregnancy-related complication. Adverse effects will be systematically assessed by study personnel at 5 time points over the course of the 10-week study and can trigger dose reductions or suspension of medication. (NCT02188459)
Timeframe: 10 week treatment phase

Number of Participants With Cessation Success at Week 10 After Target Quit Date

Intervention	adverse effects (Mean)
Placebo	.7
Bupropion	1.1

Participants will be considered to be abstinent if they self-report abstinence (not even a puff of a cigarette) for >7 days prior to the assessment after 10 weeks of treatment post-To Quit Day and have a CO <8 ppm at that time. As per convention, participants are assumed to be smoking if they self-report to be smoking at the time point, cannot be reached to provide data at the time point, fail to provide a breath sample at the time point, or provide a breath sample at the time point that has a CO concentration >8 ppm. (NCT02188459)
Timeframe: 10 weeks

Exhaled Carbon Monoxide Levels

Intervention	Participants with cessation success (Number)
Placebo Group	12
Bupropion Group	7

self-reported cessation rates at 1 month, as verified by exhaled carbon monoxide levels (NCT03024606)
Timeframe: 1 month

Number of Participants With 7-day Point Prevalence Smoking Abstinence at the End of Medication Treatment (Visit 6)

Intervention	Participants (Count of Participants)
Texting Group	8
Control Group	5

The accuracy of self-reported smoking abstinence during study visits was confirmed by an exhaled carbon monoxide (CO) levels and by urinary cotinine levels. 7-day point prevalence abstinence was defined as no cigarettes (not even a puff) in the last 7 days, levels of (CO) in exhaled air < 4 ppm, and concentrations of cotinine in urine < 50 ng/mL. At every visit, a research nurse monitored the smoking status of all subjects (amount of cigarettes per day, exhaled CO). Exhaled CO was measured using a Vitalograph carbon monoxide monitor (Lenexa, KS) according to the manufacturer's recommendations. A urine sample was collected at each visit and cotinine in urine was quantified using the validated liquid chromatography-mass spectrometry (LC/MS) method. We calculated the total number of abstinent subjects. The higher the number the better outcome. (NCT01390246)
Timeframe: Visit 6 (end of 12 weeks of medication therapy)

Number of Participants With 7-day Point Prevalence Smoking Abstinence at the End of Pregnancy (Visit 7)

Intervention	Participants (Count of Participants)
Bupropion SR	5
Placebo	1

Change in Cigarette Craving and Total Nicotine Withdrawal Symptoms Between Groups During Medication Treatment

Intervention	Participants (Count of Participants)
Bupropion SR	3
Placebo	1

Cigarette craving and withdrawal symptoms were assessed by the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS consists of 7 objectives (e.g., irritability, anxious, depressed mood, difficulty concentrating, increased appetite, insomnia, restless). Subjects were given a score on each item on a scale of 0 (not present) to 4 (severe). Summed (total) score excluding craving represent subject's symptoms of tobacco withdrawal, ranging from 0 to 28. We calculated a craving for tobacco score and a total score of withdrawal symptoms excluding craving. The higher score represent more sever craving and withdrawal. (NCT01390246)
Timeframe: During treatment: Visits 2-6 (time period between 2nd and 12th week of therapy)

Change in Cigarette Craving and Total Nicotine Withdrawal Symptoms Between Groups on the Quit Date

Intervention	MNWS Score (Mean)
	Craving for tobacco	Total score of withdrawal excluding craving
Bupropion SR	1.50	3.77
Placebo	2.07	5.35

Cigarette craving and withdrawal symptoms were assessed by the Minnesota Nicotine Withdrawal Scale (MNWS). MNWS consists of 7 objectives (e.g., irritability, anxious, depressed mood, difficulty concentrating, increased appetite, insomnia, restless). Subjects were given a score on each item on a scale of 0 (not present) to 4 (severe). Summed (total) score excluding craving represent subject's symptoms of tobacco withdrawal, ranging from 0 to 28. We calculated a craving for tobacco score and a total score of withdrawal symptoms excluding craving. The higher score represent more sever craving and withdrawal. (NCT01390246)
Timeframe: Quit date, visit 2 (one week after starting the 12-week course of therapy)

Change in Quality of Life Inventory

Intervention	MNWS Score (Mean)
	Craving for tobacco	Total score of withdrawal excluding craving
Bupropion SR	2.04	4.75
Placebo	2.33	4.88

Quality of Life Inventory (QoLI) , 7 items with 3-point rating scale for importance (1 not important, 3 very important), and 3-point rating scale for satisfaction (1 not satisfied, 3 very satisfied) in terms of health, economy, work, hobbies, relationship with partner, friendship and relationship with family. (NCT03760224)
Timeframe: 12 month

Change in Quality of Life Inventory

Intervention	scores on a scale (Mean)
Intervention	2.50
Control	2.46

EuroQoL 5-Dimension 5-Level (EQ-5D-5L)

Intervention	score on a scale (Mean)
Intervention	2.45
Control	2.31

EuroQol 5-dimension 5 level (EQ-5D-5L) health utility scores on a 1 (No problem) -5 (unable or extreme pain/ anxious) scales which assess participants mobility, self care, usual activities, pain/ discomfort and their anxiety/ depression. After obtaining the data, results were re-calculated and transferred based on Hong Kong population norm. After calculation, the total score ranged from -0.864 to 1. Higher score indicates better health status. Calculations of this scale were based on Hong Kong population provided by Wong EL and colleagues (Wong EL, Ramos-Goni JM, Cheung AW, Wong AY, Rivero-Arias O. Assessing the use of a feedback module to model EQ-5D-5L health states values in Hong Kong. The Patient-Patient-Centered Outcomes Research. 2018 Apr;11(2):235-47.). (NCT03760224)
Timeframe: 12 month

EuroQoL 5-Dimension 5-Level (EQ-5D-5L)

Intervention	score on a scale (Mean)
Intervention	0.97
Control	0.97

Intervention	score on a scale (Mean)
Intervention	0.96
Control	0.97

Frequency of Smoking Urge

Intervention	score on a scale (Mean)
Intervention	0.96
Control	0.95

Frequency (in the past week) of smoking urge will be evaluated according to their frequency of their smoking urges on a scale of 0 (none at all) to 4 (ever hour or more). (NCT03760224)
Timeframe: 12 month

Frequency of Smoking Urge

Intervention	score on a scale (Mean)
Intervention	2.04
Control	2.07

Intervention	score on a scale (Mean)
Intervention	2.09
Control	2.13

Intensity of Smoking Urge

Intervention	score on a scale (Mean)
Intervention	1.72
Control	1.73

Intensity (in the past day) of smoking urge will be evaluated according to their intensity of their smoking urges on a scale of 1 (never have smoking urges) to 5 (smoking urges every hour or more). (NCT03760224)
Timeframe: 12 month

Intensity of Smoking Urge

Intervention	score on a scale (Mean)
Intervention	1.37
Control	1.39

Intervention	score on a scale (Mean)
Intervention	1.70
Control	1.79

Nicotine Withdrawals

Intervention	score on a scale (Mean)
Intervention	1.46
Control	1.46

Minnesota Nicotine Withdrawal Scale (MNWS) using Likert-type scale for the severity ratings, ranging from 0 (not at all) to 4 (severe) in terms of their desire and craving to smoke, insomnia, awakening at night, difficulty in concentration, anxious,depressed, restless and irritable. As the 9 items were rated from 0-4, therefore, the total score ranged from 0-36. A higher score indicates participants had more withdrawal symptoms. (NCT03760224)
Timeframe: 12 month

Nicotine Withdrawals

Intervention	scores on a scale (Mean)
Intervention	10.90
Control	11.46

Intervention	scores on a scale (Mean)
Intervention	11.85
Control	12.37

Number of Participants Self-reported 7-day Abstinence at 12-month Follow-up

Intervention	scores on a scale (Mean)
Intervention	11.30
Control	11.71

Self-reported abstinence in the past 7 days at 12-month follow-up (NCT03760224)
Timeframe: 12 month

Number of Participants Self-reported 7-day Abstinence at 6-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	200
Control	216

Self-reported abstinence in the past 7 days at 6-month follow-up (NCT03760224)
Timeframe: 6 month

Number of Participants Who Passed the Biochemical Validated Abstinence at 12-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	229
Control	232

Exhaled carbon monoxide below 4ppm using a Smokerlyzer, and a saliva cotinine 10ng/ml or below using the iScreen OFD Cotinine Saliva Test Kit (NCT03760224)
Timeframe: 12 month

Number of Participants Who Passed the Biochemical Validated Abstinence at 6-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	56
Control	54

Exhaled carbon monoxide below 4ppm using a Smokerlyzer, and a saliva cotinine 10ng/ml or below using the iScreen OFD Cotinine Saliva Test Kit (NCT03760224)
Timeframe: 6 month

Number of Participants Who Reported Self-reported Continuous Abstinence

Number of Participants Who Reported Smoking Relapse at 12-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	69
Control	75

Intervention	Participants (Count of Participants)
Intervention	256
Control	257

Consuming 5 cigarettes or more in 3 consecutive days in the past 12 months (NCT03760224)
Timeframe: 12 month

Number of Participants Who Reported Smoking Relapse at 3-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	269
Control	243

Consuming 5 cigarettes or more in 3 consecutive days in the past 3 months (NCT03760224)
Timeframe: 3 month

Number of Participants Who Reported Smoking Relapse at 6-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	213
Control	202

Consuming 5 cigarettes or more in 3 consecutive days in the past 6 months (NCT03760224)
Timeframe: 6 month

Number of Participants Who Self-reported 7-day Abstinence at 3-month Follow-up

Intervention	Participants (Count of Participants)
Intervention	240
Control	227

Self-reported abstinence in the past 7 days at 3-month follow-up (NCT03760224)
Timeframe: 3 month

Article	Year
Clinical Practice Guideline of Spanish Society of Pneumology and Thoracic Surgery (SEPAR) on Pharmacological Treatment of Tobacco Dependence 2023. Archivos de bronconeumologia, 2023, Volume: 59, Issue:10 Topics: Adolescent; Alcoholism; Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pulmonary Medicine	2023
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. The Cochrane database of systematic reviews, 2023, 09-12, Volume: 9 Topics: Adult; Bupropion; Electronic Nicotine Delivery Systems; Female; Humans; Network Meta-Analysis; Nicot	2023
Pharmacological interventions for promoting smoking cessation during pregnancy. The Cochrane database of systematic reviews, 2020, 03-04, Volume: 3 Topics: Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Pregnancy Outcome	2020
Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons. American family physician, 2021, 06-15, Volume: 103, Issue:12 Topics: Adult; Anxiety Disorders; Bupropion; Counseling; Female; Humans; Pregnancy; Pregnancy Complications;	2021
Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women. Journal of midwifery & women's health, 2017, Volume: 62, Issue:3 Topics: Bupropion; Female; Fetus; Humans; Lactation; Nicotiana; Nicotine; Pregnancy; Pregnant Women; Smoking	2017
Bupropion Use During Pregnancy: A Systematic Review. The primary care companion for CNS disorders, 2017, Sep-21, Volume: 19, Issue:5 Topics: Abortion, Spontaneous; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Pregnancy; Pregnancy C	2017
Pharmacotherapy for Perinatal Depression. Clinical obstetrics and gynecology, 2018, Volume: 61, Issue:3 Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antidepressive Agents, Tricyclic; Autism Spectru	2018
Systematic Review and Meta-Analysis to Assess the Safety of Bupropion and Varenicline in Pregnancy. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2019, 07-17, Volume: 21, Issue:8 Topics: Bupropion; Case-Control Studies; Female; Humans; Nicotinic Agonists; Pregnancy; Pregnancy Complicati	2019
Pharmaceutical strategies for smoking cessation during pregnancy. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:18 Topics: Bupropion; Female; Humans; Pregnancy; Pregnancy Complications; Smoking; Smoking Cessation; Tobacco U	2018
Relapse prevention interventions for smoking cessation. The Cochrane database of systematic reviews, 2019, 02-13, Volume: 2 Topics: Behavior Therapy; Bupropion; Chewing Gum; Female; Humans; Male; Nicotine; Nicotinic Agonists; Pregna	2019
Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. The Cochrane database of systematic reviews, 2019, 06-05, Volume: 6 Topics: Behavior Therapy; Bupropion; Combined Modality Therapy; Female; Humans; Nicotinic Agonists; Nortript	2019
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. British journal of clinical pharmacology, 2014, Volume: 77, Issue:2 Topics: Adolescent; Benzazepines; Bupropion; Counseling; Drug Design; Female; Humans; Molecular Sequence Dat	2014
Cochrane review summary: Pharmacological interventions for promoting smoking cessation during pregnancy. Primary health care research & development, 2013, Volume: 14, Issue:4 Topics: Antidepressive Agents, Second-Generation; Benzazepines; Birth Weight; Bupropion; Female; Humans; Inf	2013
Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction (Abingdon, England), 2014, Volume: 109, Issue:9 Topics: Antidepressive Agents, Second-Generation; Behavior Therapy; Benzazepines; Bupropion; Counseling; Fem	2014
Is it safe to use smoking cessation therapeutics during pregnancy? Expert opinion on drug safety, 2014, Volume: 13, Issue:12 Topics: Animals; Benzazepines; Bupropion; Female; Humans; Pregnancy; Quinoxalines; Smoking; Smoking Cessatio	2014
Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force. Annals of internal medicine, 2015, Oct-20, Volume: 163, Issue:8 Topics: Adult; Behavior Therapy; Bupropion; Counseling; Electronic Nicotine Delivery Systems; Female; Humans	2015
Smoking Cessation Strategies in Pregnancy. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2015, Volume: 37, Issue:9 Topics: Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Nicotinic Agonists; Pregnancy; Smoking Cessat	2015
Pharmacological interventions for promoting smoking cessation during pregnancy. The Cochrane database of systematic reviews, 2015, Dec-22, Issue:12 Topics: Bupropion; Female; Humans; Nicotinic Agonists; Pregnancy; Pregnancy Complications; Pregnancy Outcome	2015
[Treatment of smoking cessation during pregnancy]. Tuberkuloz ve toraks, 2008, Volume: 56, Issue:2 Topics: Adult; Antidepressive Agents, Second-Generation; Behavior Therapy; Bupropion; Chewing Gum; Combined	2008
Smoking cessation in pregnancy. Expert opinion on drug safety, 2008, Volume: 7, Issue:6 Topics: Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Nicotine; Nicotinic Ag	2008
Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring. Therapeutic advances in respiratory disease, 2009, Volume: 3, Issue:4 Topics: Animals; Antioxidants; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Maternal	2009
What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2009, Volume: 11, Issue:11 Topics: Animals; Benzazepines; Bupropion; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fem	2009
Current approaches to pharmacotherapy for smoking cessation. Therapeutic advances in respiratory disease, 2010, Volume: 4, Issue:1 Topics: Adolescent; Adult; Animals; Benzazepines; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Mal	2010
A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction (Abingdon, England), 2010, Volume: 105, Issue:8 Topics: Bupropion; Counseling; Dopamine Uptake Inhibitors; Female; Humans; Nicotinic Agonists; Patient Educa	2010
Pharmacotherapy for smoking cessation: present and future. Current pharmaceutical design, 2011, Volume: 17, Issue:14 Topics: Adolescent; Animals; Benzazepines; Bupropion; Delayed-Action Preparations; Female; Humans; Nicotine;	2011
Efficacy and safety of pharmacotherapy for smoking cessation among pregnant smokers: a meta-analysis. BJOG : an international journal of obstetrics and gynaecology, 2012, Volume: 119, Issue:9 Topics: Adult; Benzazepines; Bupropion; Controlled Clinical Trials as Topic; Dopamine Uptake Inhibitors; Epi	2012
Managing nicotine addiction. Journal of dental education, 2002, Volume: 66, Issue:9 Topics: Administration, Inhalation; Adolescent; Adult; Antidepressive Agents, Tricyclic; Bupropion; Chewing	2002
Pharmacotherapies to enhance smoking cessation during pregnancy. Drug and alcohol review, 2003, Volume: 22, Issue:2 Topics: Administration, Cutaneous; Administration, Inhalation; Administration, Intranasal; Antidepressive Ag	2003
Pharmacotherapy for smoking cessation during pregnancy. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2004, Volume: 6 Suppl 2 Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Female; Ganglionic Stimulants; Humans; Nicotine; Pregn	2004
Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug and alcohol review, 2006, Volume: 25, Issue:1 Topics: Adolescent; Adult; Bupropion; Clinical Trials as Topic; Clonidine; Drug Administration Routes; Femal	2006
Smoking cessation in pregnancy: why, how, and what next... Clinical obstetrics and gynecology, 2008, Volume: 51, Issue:2 Topics: Behavior Therapy; Benzazepines; Bupropion; Counseling; Female; Humans; Nicotine; Pregnancy; Pregnanc	2008
Issues in the treatment of women with bipolar illness. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 15 Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; Buprop	1997
Pharmacotherapy of smoking cessation. Archives of family medicine, 2000, Volume: 9, Issue:3 Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Bup	2000
[Treatment of nicotine addiction. Drug therapy for smoking cessation]. Ugeskrift for laeger, 2002, Mar-11, Volume: 164, Issue:11 Topics: Administration, Inhalation; Administration, Intranasal; Antidepressive Agents, Second-Generation; Bu	2002
The pharmacotherapy of smoking cessation. The Medical journal of Australia, 2002, May-20, Volume: 176, Issue:10 Topics: Antidepressive Agents, Second-Generation; Bupropion; Chewing Gum; Contraindications; Female; Humans;	2002

Article	Year
A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial. Addiction (Abingdon, England), 2023, Volume: 118, Issue:7 Topics: Adult; Bupropion; Central Nervous System Stimulants; Double-Blind Method; Drug Therapy, Combination;	2023
Placebo-controlled trial of bupropion for smoking cessation in pregnant women. American journal of obstetrics & gynecology MFM, 2021, Volume: 3, Issue:6 Topics: Bupropion; Female; Humans; Infant; Infant, Newborn; Pregnancy; Pregnancy Outcome; Pregnant Women; Sm	2021
Smoking Cessation Following Text Message Intervention in Pregnant Women. The Annals of pharmacotherapy, 2018, Volume: 52, Issue:11 Topics: Adult; Bupropion; Female; Follow-Up Studies; Humans; Maternal Health; Motivation; Pregnancy; Prenata	2018
Randomized, controlled pilot trial of bupropion for pregnant smokers: challenges and future directions. American journal of perinatology, 2015, Volume: 32, Issue:4 Topics: Adult; Bayes Theorem; Bupropion; Double-Blind Method; Female; Humans; Pilot Projects; Poverty; Pregn	2015
Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. American journal of obstetrics and gynecology, 2017, Volume: 216, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Breath Tests; Bupropion; Carbon Dioxide; Cotinine;	2017
The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. The American journal of drug and alcohol abuse, 2010, Volume: 36, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder, Major;	2010
Bupropion SR for the treatment of postpartum depression: a pilot study. The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:3 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression, Postpartum; Diag	2005
Smoking cessation medication use among pregnant and postpartum smokers. Obstetrics and gynecology, 2008, Volume: 111, Issue:2 Pt 1 Topics: Adult; Bupropion; Counseling; Educational Status; Female; Health Care Costs; Humans; Marital Status;	2008

Article	Year
Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study. Pharmacotherapy, 2021, Volume: 41, Issue:11 Topics: Antidepressive Agents; Bupropion; Citalopram; Duloxetine Hydrochloride; Escitalopram; Female; Fluoxe	2021
Environmental enrichment affects behavioral and pharmacological response to antidepressants in CF1 mice. Neuroscience letters, 2023, 09-14, Volume: 813 Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Bupropion; Fema	2023
Health-care providers' concern regarding smoking cessation pharmacotherapies during pregnancy: Calls to a teratology information service. Drug and alcohol review, 2020, Volume: 39, Issue:3 Topics: Australia; Behavior Therapy; Bupropion; Call Centers; Female; Health Personnel; Humans; Information	2020
Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2020, 10-08, Volume: 22, Issue:10 Topics: Analgesics, Opioid; Bupropion; Cotinine; Female; Humans; Methadone; Nicotine; Opiate Substitution Tr	2020
Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA psychiatry, 2020, 12-01, Volume: 77, Issue:12 Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Bupropion; Case-Control Studies; Child; Female; Huma	2020
Development and Validation of a Model to Predict Neonatal Abstinence Syndrome. The Journal of pediatrics, 2021, Volume: 229 Topics: Adult; Analgesics; Antiemetics; Antipsychotic Agents; Benzodiazepines; Bupropion; Female; Gabapentin	2021
Why the Maternal Medication List Matters: Neonatal Toxicity From Combined Serotonergic Exposures. Pediatrics, 2021, Volume: 147, Issue:2 Topics: Antidepressive Agents; Bipolar Disorder; Brain Diseases; Bupropion; Drug Therapy, Combination; Dyski	2021
Pregnancy Has No Clinically Significant Effect on the Pharmacokinetics of Bupropion or Its Metabolites. Therapeutic drug monitoring, 2021, 12-01, Volume: 43, Issue:6 Topics: Antidepressive Agents; Bupropion; Female; Humans; Placenta; Postpartum Period; Pregnancy	2021
Medicaid Coverage of Smoking Cessation Counseling and Medication Is Underutilized for Pregnant Women. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2017, May-01, Volume: 19, Issue:5 Topics: Adult; Bupropion; Counseling; Databases, Factual; Dopamine Uptake Inhibitors; Female; Humans; Insura	2017
The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone. Drug metabolism letters, 2017, 11-17, Volume: 11, Issue:1 Topics: Antidepressive Agents; Biotransformation; Bupropion; Cigarette Smoking; Female; Humans; Microsomes;	2017
Paternal exposure to bupropion affects postnatal development in the offspring. Reproduction, fertility, and development, 2019, Volume: 31, Issue:10 Topics: Animals; Animals, Newborn; Behavior, Animal; Bupropion; Female; Growth and Development; Male; Mice;	2019
Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. Reproductive sciences (Thousand Oaks, Calif.), 2013, Volume: 20, Issue:10 Topics: Animals; Animals, Newborn; Bupropion; Female; Male; Pregnancy; Prenatal Exposure Delayed Effects; Ra	2013
First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:10 Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion;	2014
ADHD and pregnancy. The American journal of psychiatry, 2014, Volume: 171, Issue:7 Topics: Adult; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants;	2014
Metabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus). Drug metabolism and disposition: the biological fate of chemicals, 2014, Volume: 42, Issue:10 Topics: Animals; Biotransformation; Bupropion; Female; Papio cynocephalus; Postpartum Period; Pregnancy; Pre	2014
Evaluation of bupropion hydrochloride developmental cardiotoxic effects in chick cardiomyocyte micromass culture and stem cell derived cardiomyocyte systems. Birth defects research. Part B, Developmental and reproductive toxicology, 2014, Volume: 101, Issue:5 Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Cardiotoxins; Cell Differentiation; Ce	2014
Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. Annals of internal medicine, 2015, Oct-20, Volume: 163, Issue:8 Topics: Adult; Behavior Therapy; Biomedical Research; Bupropion; Cost of Illness; Counseling; Electronic Nic	2015
Summaries for Patients. Behavioral and Pharmacologic Treatments to Help Adults Quit Smoking: U.S. Preventive Services Task Force Recommendation Statement. Annals of internal medicine, 2015, Oct-20, Volume: 163, Issue:8 Topics: Adult; Behavior Therapy; Bupropion; Counseling; Electronic Nicotine Delivery Systems; Female; Humans	2015
Drugs for smoking cessation. BMJ (Clinical research ed.), 2016, Feb-23, Volume: 352 Topics: Bupropion; Contraindications; Dopamine Uptake Inhibitors; Drug Monitoring; Female; Humans; Middle Ag	2016
Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women. American family physician, 2016, May-15, Volume: 93, Issue:10 Topics: Adult; Behavior Therapy; Bupropion; Counseling; Female; Humans; Pregnancy; Pregnancy Complications;	2016
Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: Recommendation Statement. American family physician, 2016, May-15, Volume: 93, Issue:10 Topics: Adult; Behavior Therapy; Bupropion; Combined Modality Therapy; Counseling; Electronic Nicotine Deliv	2016
Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:4 Topics: Adult; Amniotic Fluid; Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Feta	2016
Success of smoking cessation interventions during pregnancy. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:5 Topics: Adolescent; Adult; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Infant, Newborn; Infant, P	2016
Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. Drug metabolism and disposition: the biological fate of chemicals, 2016, Volume: 44, Issue:11 Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Cytochrome P-450 CYP2B6; Cytoch	2016
Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies. Reproductive sciences (Thousand Oaks, Calif.), 2017, Volume: 24, Issue:6 Topics: Animals; Bupropion; Female; Heart; Myocytes, Cardiac; Pregnancy; Prenatal Exposure Delayed Effects;	2017
What's new in nicotine & tobacco research? Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2008, Volume: 10, Issue:6 Topics: Adolescent; Adolescent Behavior; Adult; Bupropion; Female; Humans; Male; Pregnancy; Pregnancy Compli	2008
Prescribing during pregnancy. Prenatal drug exposure and an untreated psychiatric disorder both present risks. The Harvard mental health letter, 2008, Volume: 25, Issue:6 Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Bupropion; Depressive Disorder; Dopamine Uptake	2008
[Varenicline - pharmacological therapy of tobacco dependence]. Wiener medizinische Wochenschrift (1946), 2009, Volume: 159, Issue:1-2 Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Clinical Trials as Topic; Contraindications; Doubl	2009
Transplacental transfer and metabolism of bupropion. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2010, Volume: 23, Issue:5 Topics: Bupropion; Cell Survival; Chorionic Gonadotropin; Dopamine Uptake Inhibitors; Female; Humans; Matern	2010
Bupropion metabolism by human placenta. Biochemical pharmacology, 2010, Jun-01, Volume: 79, Issue:11 Topics: 11-beta-Hydroxysteroid Dehydrogenases; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hy	2010
Patterns of tobacco exposure before and during pregnancy. Acta obstetricia et gynecologica Scandinavica, 2010, Volume: 89, Issue:4 Topics: Adult; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Female; Fertilization; Humans; Infant,	2010
Maternal use of bupropion and risk for congenital heart defects. American journal of obstetrics and gynecology, 2010, Volume: 203, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Chi-Square Distrib	2010
Fetal cardiac arrhythmia during bupropion use. Acta obstetricia et gynecologica Scandinavica, 2010, Volume: 89, Issue:7 Topics: Adult; Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Atrial Premature Complexes; B	2010
Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochemical pharmacology, 2010, Oct-01, Volume: 80, Issue:7 Topics: Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport	2010
Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. Journal of developmental and behavioral pediatrics : JDBP, 2010, Volume: 31, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bipo	2010
Patterns of antidepressant medication use among pregnant women in a United States population. Journal of clinical pharmacology, 2011, Volume: 51, Issue:2 Topics: Antidepressive Agents; Bupropion; Case-Control Studies; Female; Humans; Pregnancy; Pregnancy Complic	2011
State medicaid coverage for tobacco-dependence treatments --- United States, 2009. MMWR. Morbidity and mortality weekly report, 2010, Oct-22, Volume: 59, Issue:41 Topics: Bupropion; Dopamine Uptake Inhibitors; Eligibility Determination; Fee-for-Service Plans; Female; Gan	2010
Metabolism of bupropion by baboon hepatic and placental microsomes. Biochemical pharmacology, 2011, Aug-01, Volume: 82, Issue:3 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Female; Liver; Microsomes; Molecular Structure; Papi	2011
Hyperinsulinism associated with gestational exposure to bupropion in a newborn infant. Journal of pediatric endocrinology & metabolism : JPEM, 2011, Volume: 24, Issue:9-10 Topics: Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Hyperinsulinism; Hypoglycemia;	2011
Real world evaluation of three models of NHS smoking cessation service in England. BMC research notes, 2012, Jan-06, Volume: 5 Topics: Adolescent; Adult; Benzazepines; Bupropion; Community Health Services; Counseling; England; Female;	2012
DNA methylation in neonates born to women receiving psychiatric care. Epigenetics, 2012, Volume: 7, Issue:4 Topics: Antidepressive Agents; Antiemetics; Bupropion; CpG Islands; Depressive Disorder, Major; DNA Methylat	2012
Bupropion: congenital heart defects (continued). Prescrire international, 2012, Volume: 21, Issue:126 Topics: Bupropion; Dopamine Uptake Inhibitors; Drug Monitoring; Female; Heart Defects, Congenital; Humans; I	2012
Promoting smoking cessation. American family physician, 2012, Mar-15, Volume: 85, Issue:6 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Complementary	2012
Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2012, Volume: 70 Topics: Acetonitriles; Biotransformation; Buffers; Bupropion; Calibration; Chemical Precipitation; Chromatog	2012
Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:2 Topics: Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Carbamazepine; Cell	2013
Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:11 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Abnormalities	2012
Bupropion can close KATP channel and induce insulin secretion. Journal of pediatric endocrinology & metabolism : JPEM, 2013, Volume: 26, Issue:3-4 Topics: Animals; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Hyperinsulinism; Infan	2013
Serum bupropion levels in 2 breastfeeding mother-infant pairs. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10 Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Breast Feeding; Bupropion; Depres	2002
Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. European journal of clinical pharmacology, 2003, Volume: 59, Issue:10 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bupropion; Coho	2003
Suicide in pregnancy. Obstetrics and gynecology, 2003, Volume: 102, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Female; Humans; Pregna	2003
[Recommendation of good practice: Therapeutic strategies, with or without the assistance of medicine-based treatment, for stopping smoking (May 2003)]. Gynecologie, obstetrique & fertilite, 2004, Volume: 32, Issue:5 Topics: Adolescent; Alcohol Drinking; Bupropion; Cotinine; Female; Humans; MEDLINE; Nicotine; Pregnancy; Smo	2004
Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. American journal of obstetrics and gynecology, 2005, Volume: 192, Issue:3 Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antidepressive Agents, Second-Generation; Birth	2005
Effectiveness of bupropion for smoking cessation during pregnancy. Journal of addictive diseases, 2005, Volume: 24, Issue:2 Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Female; Humans; Pregnancy; Pregnancy Complications; Se	2005
Bupropion (amfebutamone): caution during pregnancy. Prescrire international, 2005, Volume: 14, Issue:80 Topics: Amphetamines; Antidepressive Agents, Second-Generation; Bupropion; Congenital Abnormalities; Contrai	2005
Prenatal bupropion exposure enhances the cocaine reward and stress susceptibility in adult mice. The Chinese journal of physiology, 2005, Dec-31, Volume: 48, Issue:4 Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Cocaine; Conditio	2005
Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:5 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Congenital Abnormalities; Da	2007
Prenatal exposure of bupropion may enhance agitation, anxiety responses, and sensitivity to cocaine effects in adult mice. The Chinese journal of physiology, 2007, Feb-28, Volume: 50, Issue:1 Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cocaine; Dose-Response	2007
Psychopharmacology news. New side effects of agents. Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:3 Topics: Benzodiazepines; Bupropion; Female; Humans; Olanzapine; Pregnancy; Propranolol; Psychotropic Drugs;	2007
Stat bite: Medicaid coverage of tobacco-dependence treatments. Journal of the National Cancer Institute, 2008, Apr-02, Volume: 100, Issue:7 Topics: Administration, Cutaneous; Administration, Intranasal; Administration, Oral; Antidepressive Agents,	2008
Preclinical toxicology of bupropion: an overview. The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Pt 2 Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents; Bupropion; Central Nervous System; Chem	1983
The use of pharmacotherapies for smoking cessation during pregnancy. Tobacco control, 2000, Volume: 9 Suppl 3 Topics: Antidepressive Agents; Bupropion; Education; Female; Health Promotion; Humans; Nortriptyline; Pregna	2000
Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax, 2000, Volume: 55, Issue:12 Topics: Behavior Therapy; Bupropion; Evidence-Based Medicine; Family Practice; Female; Humans; National Heal	2000
Cutaneous drug reaction case reports: from the world literature. American journal of clinical dermatology, 2002, Volume: 3, Issue:1 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Bupropion; Celecoxib; Chlorquinaldol; Cytarabi	2002
Control of prolactin release induced by suckling. Endocrinology, 1987, Volume: 121, Issue:1 Topics: Animals; Bupropion; Dopamine; Female; Hypothalamus; Immunization, Passive; Lactation; Methysergide;	1987

bupropion and Pregnancy

Research Excerpts

Research

Studies (107)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Birth Outcomes 5-minute Appearance, Pulse, Grimace, Activity, and Respiration Score

Birth Outcomes for Gestational Age

Birth Outcomes Head Circumference.

Birth Outcomes, Size (Percentile) for Gestational Age.

Birth Weight Outcomes

Number Moderate or Severe Side Effects

Number of Participants With Cessation Success at Week 10 After Target Quit Date

Exhaled Carbon Monoxide Levels

Number of Participants With 7-day Point Prevalence Smoking Abstinence at the End of Medication Treatment (Visit 6)

Number of Participants With 7-day Point Prevalence Smoking Abstinence at the End of Pregnancy (Visit 7)

Change in Cigarette Craving and Total Nicotine Withdrawal Symptoms Between Groups During Medication Treatment

Change in Cigarette Craving and Total Nicotine Withdrawal Symptoms Between Groups on the Quit Date

Change in Quality of Life Inventory

Change in Quality of Life Inventory

EuroQoL 5-Dimension 5-Level (EQ-5D-5L)

EuroQoL 5-Dimension 5-Level (EQ-5D-5L)

EuroQoL 5-Dimension 5-Level (EQ-5D-5L)

Frequency of Smoking Urge

Frequency of Smoking Urge

Frequency of Smoking Urge

Intensity of Smoking Urge

Intensity of Smoking Urge

Intensity of Smoking Urge

Nicotine Withdrawals

Nicotine Withdrawals

Nicotine Withdrawals

Number of Participants Self-reported 7-day Abstinence at 12-month Follow-up

Number of Participants Self-reported 7-day Abstinence at 6-month Follow-up

Number of Participants Who Passed the Biochemical Validated Abstinence at 12-month Follow-up

Number of Participants Who Passed the Biochemical Validated Abstinence at 6-month Follow-up

Number of Participants Who Reported Self-reported Continuous Abstinence

Number of Participants Who Reported Smoking Relapse at 12-month Follow-up

Number of Participants Who Reported Smoking Relapse at 3-month Follow-up

Number of Participants Who Reported Smoking Relapse at 6-month Follow-up

Number of Participants Who Self-reported 7-day Abstinence at 3-month Follow-up

Number of Participants Who Self-reported Continuous Abstinence

Number of Participants Who Self-reported Continuous Abstinence

Reviews

Trials

Other Studies